In 1997, seven cases of a new subtype of diffuse large B-cell lymphoma expressing the anaplastic lymphoma kinase gene product (ALK-DLBCL) were reported by Delsol et al. 1 This lymphoma was identified due to its characteristic lack of CD30 expression in an otherwise large series of classical T-/null cell ALK-positive anaplastic large cell lymphomas (ALCL). 1 ALK-DLBCL exhibits an immunoblastic/plasmablastic morphology, often an intrasinusoidal growth pattern, and is derived from B cells based on expression of monotypic light chain. It shows an unique immunophenotypic profile characterized by a lack of B (CD20, CD79a)-and T-lineage (CD3) markers and CD30, but expression of VS38 and CD138 (plasmacytic markers), variable expression of CD4 and CD57, and cytoplasmic, granular ALK reactivity.
Initially, molecular and protein analyses failed to reveal an ALK gene rearrangement. 1 Recently however, Clathrin/ALK (CLTC/ALK) and NPM/ALK gene rearrangements have been identified in 16 and three cases of ALK-DLBCL, respectively. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] All of these cases display the morphologic and immunophenotypic features of ALK-DLBCL, as originally described by Delsol et al. Importantly, ALK positivity and ALK gene rearrangements can be seen in B-cell lymphomas and are now no longer uniquely restricted to the T-cell lymphoma, ALCL. To our knowledge, only 29 cases of ALK-DLBCL have been reported thus far in the literature. Herein, we report detailed clinical and pathologic features of four new adult cases of this rare entity.
Materials and methods
Four total cases of ALK-positive DLBCL were identified: three from the hematology consultation files at the University of Texas Southwestern Medical Center from 1997 to 2002 and one from University of New Mexico, 2006. One case was originally diagnosed as an anaplastic plasmacytoma, but was subsequently reclassified. Clinical and laboratory information for each of the four patients was obtained through physician interview. The mean disease-free survival for low stage patients (alive with disease) and the overall median survival for high stage patients (dead of disease) were calculated from the data reported in the literature.
Routine hematoxylin and eosin-stained sections were prepared from formalin-fixed and/or B5-fixed paraffin blocks. Immunohistochemical analysis included a broad panel of antibodies (Table 1) . Fresh tissue from case 2 was submitted for flow cytometric analysis. The cell preparation and data analysis were performed as previously described. 14 Fluorescence in situ hybridization (FISH) for the Clathrin/ALK fusion associated with t(2;17) (p23;q23) was performed on case 3 as previously described. 2 FISH evaluation for an ALK gene rearrangement using the ALK break apart probe from Vysis, Inc. (Downers Grove, IL, USA) was performed on case 4 on a paraffin-embedded tissue section.
Genetic studies could not be attempted on the other two cases owing to lack of available remaining specimen.
Results

Case Reports
A summary of the clinical features of the four patients is provided in Table 2 . All patients were adults; two female and two male.
Case 1
A 41-year-old female presented with left cervical lymphadenopathy (2.8 Â 1.8 Â 1.0 cm). Hematologic studies, lactate dehydrogenase, and serum protein electrophoresis were all within normal limits. A computed tomography (CT) scan of the thorax and abdomen showed no mass lesions or additional lymphadenopathy. An excisional biopsy of the lymph node was performed. A staging bone marrow was negative for involvement by lymphoma. The patient underwent six cycles of CHOP followed by left neck irradiation for stage 1 disease. Follow-up imaging studies show no evidence of lymphoma. At 58 months, she was alive without disease.
Case 2
A 49-year-old female presented with an enlarged left cervical lymph node that she had noticed for about 1 month. She was otherwise asymptomatic and had no significant past medical history. Hematologic and liver function studies were within normal limits. A CT scan of the neck revealed left submandibular lymphadenopathy. CT scans of the head, chest, pelvis, and abdomen were unremarkable. Biopsy of the left cervical lymph node was performed. Staging bone marrow was negative for involvement by lymphoma. She received four cycles of CHOP followed by involved field irradiation for stage 1 disease. At 36 months, she was alive and free of disease.
Case 3
A 71-year-old male presented with a chief complaint of hemoptysis for six weeks. Physical exam revealed a large nasopharyngeal mass (approximately 5.5 cm) without peripheral lymphadenopathy. CBC showed mild normochromic, normocytic anemia. CT scan demonstrated abdominal and retroperitoneal lymphadenopathy. A biopsy of the nasopharyngeal mass was performed. A staging bone marrow showed low level involvement by chronic lymphocytic leukemia, but no evidence of large cell lymphoma. The patient received CHOP and nasopharyngeal irradiation for stage IV disease. Follow-up imaging Immunohistochemistry Table 3 provides a summary of the immunohistochemical results in our four cases. All tested cases were positive for CD138, monotypic cytoplasmic light chain and CD4 ( negative. CD38 was negative by immunohistochemistry in three cases, but positive by flow cytometry in one. IgA staining was equivocal in three cases. Cases 1, 2, 3, and 4 exhibited 50, 50, 80, and 50% proliferation indices by Ki-67 staining, respectively. 
Flow Cytometry
Four-color flow cytometric analysis performed on tissue from case 2 revealed a 1% population of medium to large size cells (based on forward and side angle light scatter properties) expressing CD45, CD4, CD38 (moderate), and HLA-DR ( Figure 5 ). The tumor cells were negative for CD2, CD3, CD5, CD7, CD8, CD10, CD14, CD19, CD20, CD23, FMC7, CD33, and surface kappa and lambda light chains.
FISH for ALK Gene Rearrangement
FISH demonstrated an ALK gene rearrangement in case 4. Figure 6 demonstrates a clearly separated orange and green signal indicating a rearrangement of the ALK gene (arrows). The normal ALK gene signal is seen as overlapping/fusion of the orange and green signals (yellow). As the ALK probe is a break apart probe, the translocation partner remains unknown (eg Clathrin (CLTC) or NPM, etc.). However, given the cytoplasmic granular staining pattern with ALK immunohistochemistry, it is most likely that the partner is CLTC. FISH analysis on case 3 technically failed owing to lack of detectable hybridization signal.
Discussion
We report four cases of anaplastic lymphoma kinasepositive diffuse large B-cell lymphoma (ALK-DLBCL) based on morphologic and immunophenotypic similarity to those previously described. [1] [2] [3] [4] [5] [6] ALK-DLBCL was initially described by Delsol et al in 1997. 1 Our study of four cases brings the total number of reported cases of ALK-DLBCL in the literature to 33.
ALK-DLBCL has a distinct morphologic appearance with immunoblastic/plasmablastic cytology with round, centrally to eccentrically located nuclei, prominent single central nucleoli, and moderate amounts of variably eosinophilic cytoplasm ( Figures  1 and 2) . A sinusoidal growth pattern may be seen (Figure 1a) . Immunohistochemically, ALK-DLBCL shows features suggesting plasmacytic differentiation, with positivity for EMA, CD138, VS38c, and monotypic cytoplasmic light chain. The characteristic ALK staining is usually cytoplasmic and coarsely granular (attributed to the presence of the Clathrin-ALK fusion). Occasional cases with nuclear and cytoplasmic positivity have also been reported (Table 4) . CD4, CD57, and CD45 are variably positive, and CD30, EBV, CD43, B-cell related antigens (CD20 and CD79a), and T-cell related antigens (CD3) are negative. Table 5 presents a summary of the frequency of common immunohistochemical findings. Delsol et al also found that a majority (5/7) of their cases expressed monotypic IgA lambda, which has also been subsequently reported by others. We and others have found that no cases express CD56 or TIA-1.
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Although a fairly typical immunohistochemical (plasmacytic) profile has been established for ALK-DLBCL, it is clear that some immunophenotypic heterogeneity exists. In one of our four cases, CD20 highlighted rare positive tumor cells, providing a helpful clue to the underlying B lineage. CD20 positivity, even focal, is distinctly unusual. We show one case with scattered cytokeratin (AE1/ AE3)-positive tumor cells, which in conjunction with EMA positivity may lead to an erroneous interpretation of carcinoma. In addition, although usually negative, De Paepe et al 3 report one of their three cases as being CD30 positive.
The overall morphologic and immunohistochemical features should allow for distinction of ALK-DLBCL from other entities including ALCL, plasmablastic lymphoma, plasmablastic myeloma, anaplastic variant of diffuse large B-cell lymphoma, and carcinoma. ALCL is typically CD30( þ ), of T-cell phenotype and would be negative for plasma cell markers (CD138) and immunoglobulin light chain. Plasmablastic lymphomas often occur in the oral region of human immunodeficiency virus-infected individuals, and are EBER positive and ALK negative. 15 The anaplastic variant of DLBCL is usually strong CD20( þ ) and ALK(À). Plasmablastic myeloma has not been reported to be ALK positive, and would be associated with other features such as lytic bone lesions and a monoclonal protein in serum and/or urine.
The clinical features from the 33 reported cases of ALK-DLBCL are summarized in Tables 2 and 6 . ALK-DLBCL spans all age groups with an overall male predominance (M:F ratio of 3:1). The M:F ratio is similar in children (7:3) and adults (18:5) . Commonly reported clinical features included lymphadenopathy (27 cases), hepato-and/or splenomegaly (four cases), bony/CNS extension (four cases), mediastinal mass (four cases), and laryngeal/oral mass (three cases). Although only 33 cases of ALK-DLBCL have been reported thus far, higher stage disease at presentation (III-IV) appears to correlate with a poor response to multiagent lymphoma chemotherapy and an aggressive clinical course ( Table 6 ). The overall median survival of high stage III/IV patients (N ¼ 13) was 11 months. Of the 11 patients reported as low stage I/II with at least 14 months follow-up, the average disease-free survival was 41 months (N ¼ 10). Only one was dead of disease after 14 months (Table 6 ).
The recent discovery of underlying ALK rearrangements in ALK-DLBCL is an important advance in our understanding of the pathogenesis of this lymphoma. [2] [3] [4] [5] [6] The ALK gene located on chromosome 2p23 may be translocated to either the Clathrin (CLTC) gene locus on chromosome 17q23 or to the nucleophosmin (NPM) gene on chromosome 5q35, resulting in CLTC-ALK and NPM-ALK fusion products, respectively [2] [3] [4] [5] [6] [8] [9] [10] [11] (Table 4) . Both of these genetic rearrangements were originally identified in classic ALK( þ ) ALCL, with NPM-ALK being distinctly more common (70-80% of cases). 16 As in ALCL, the ALK staining pattern in ALK-DLBCL appears to correlate with the type of underlying rearrangement. Cases with CLTC-ALK/t(2;17) rearrangement show a distinctly cytoplasmic and granular ALK staining pattern, whereas those cases with an NPM-ALK/t(2;5) rearrangement show both cytoplasmic and nuclear staining. [2] [3] [4] [5] [6] [8] [9] [10] [11] 16 However, this correlation may be imperfect, as Onciu et al 5 reported one case of ALK-DLBCL with NPM-ALK fusion that showed cytoplasmic ALK staining only. Thus, ALK gene rearrangements, originally thought to be uniquely associated with T-/null cell ALCL, have now been convincingly shown to occur in rare cases of B-cell lymphoma. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] Of note, prior to the initial series by Delsol et al, 1 Arber et al 17 in 1996 reported NPM/ALK fusion transcripts (by RT-PCR) in four of 33 cases of large B-cell lymphoma. Interestingly, and in contrast to the cases of ALK-DLBCL reported thus far, these four cases had a conventional B-cell immunophenotype (CD20 þ and CD79a þ ). All cases were EMA(À) and one case had focal (o10%) CD30 positivity. ALK aberrations, specifically involving rearrangements of the CLTC gene, have also been identified in some cases of inflammatory myofibroblastic tumors (IMT). 18 Thus, ALK overexpression likely contributes to the pathogenesis of a variety of otherwise unrelated neoplasms, ALK-DLBCL, ALCL, and IMT.
